Michaela Levin - 31 Aug 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Business Officer
Issuer ticker: ACRV
Reported as of: 31 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2026, 16:30:31 UTC
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Michaela Levin filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 02 Sep 2026.

Key facts

This page summarizes Michaela Levin's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Sep 2026, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002151012 Primary reporting owner

Levin Michaela

Relationship: Chief Business Officer
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 02 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 31 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +130,000
Change %
Price: $0.000000^*
Shares after: 130,000
Date: 31 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 130,000
Exercise price: $2.09
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.